Regentis BiomaterialsRGNT
13F holders, Q1 2026 (March 31)3holders
2new positions
2sold out
$3.06avg. 13F price*
At the end of Q1 2026, 3 institutions reported holding Regentis Biomaterials Ltd. (RGNT) in their 13F filings, unchanged from Q4 2025. 2 opened new positions and 2 sold out. The largest holders were AIGH Capital Management LLC ($917K), Rosalind Advisors, Inc. ($768K) and UBS Group AG ($1K).
- Company
- Regentis Biomaterials Ltd.
- CUSIP
- M8211G108
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $918K |
| Exits | 2 | $197K |
All 13F filers, Q4 2025 → Q1 2026: 300,334 shares bought and 29,505 shares sold, net +270,829 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| AIGH Capital Management LLC | 0.19% | New | 300,000 | $917K |
| Rosalind Advisors, Inc. | 0.31% | No change | 251,510 | $768K |
| UBS Group AG | 0.00% | New | 334 | $1K |
"% of holder's portfolio" is RGNT's weight in each manager's 13F, not the share of Regentis Biomaterials Ltd. the manager owns.